sodium valproate

EC 213-961-8

Also known as Epilim and valproate.

Latest news on sodium valproate

19 November 2026
Johnson & Johnson files for CAPLYTA approval in bipolar mania

Two Phase 3 trials found symptom improvement by Day 3, sustained through Week 3; approval would add another adult use.

10 November 2026
Johnson & Johnson reports positive Phase 3 mania results for CAPLYTA

A second pivotal study found improvement in symptoms by Day 3; the findings will support a planned US regulatory submission.

8 September 2026
Johnson & Johnson to present neuropsychiatry data at Psych Congress 2026

24 abstracts at Psych Congress will report Phase 3 CAPLYTA data in bipolar mania, SPRAVATO analyses on anhedonia, seltorexant MDD+insomnia results, and LAI real‑world studies.

4 May 2026
Johnson & Johnson: CAPLYTA tops adjunctive MDD antipsychotics in network meta-analysis

Network meta-analysis of 10 trials found an adjunctive atypical antipsychotic superior on MADRS change, response, remission and CGI‑S, with no significant weight gain and favorable tolerability.